Integrated Filing — IndAS

General information about company

Scrip Code	544645
NSE Symbol	PARKHOSPS
MSEI Symbol	NOTLISTED
ISIN	INE119201023
Name of company	Park Medi World Limited
Type of company	Main Board
Class of security	Equity
Date of start of financial year	01-04-2025
Date of end of financial year	31-03-2026
Date of board meeting when results were approved	28-01-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	22-01-2026
Description of presentation currency	INR
Level of rounding used in financial results	Lakhs
Reporting Type	Quarterly
Reporting Quarter	Third quarter
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited for the quarter ended	Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	Unaudited
Segment Reporting	Single segment
Description of single segment	Healthcare Services
Start date and time of board meeting	28-01-2026 09:00:00
End date and time of board meeting	28-01-2026 11:48:00
Whether cash flow statement is applicable on company
Type of cash flow statement
Declaration of unmodified opinion or statement on impact of audit qualification	Not applicable
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?	Yes
No. of times funds raised during the quarter	1
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?	No
The Company has not defaulted on any loans and debt securities during quarter ended December 31, 2025

Financial Results Ind-AS

Amount in (Lakhs)

Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-10-2025	01-04-2025
B	Date of end of reporting period	31-12-2025	31-12-2025
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone	Standalone
1	Income
	Revenue from operations	4,587.00	10,153.20
	Other income	551.70	206.50
	Total income	5,138.70	10,359.70
2	Expenses
(a)	Cost of materials consumed	592.40	1,230.40
(b)	Purchases of stock-in-trade	0.00	0.00
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(35.40)	(39.70)
(d)	Employee benefit expense	737.30	1,442.80
(e)	Finance costs	360.80	1,033.40
(f)	Depreciation, depletion and amortisation expense	117.60	349.90
(f)	Other Expenses
1	Professional and consultancy fees	568.70	858.50
2	Other expenses	922.10	1,901.40
	Total other expenses	1,490.80	2,759.90
	Total expenses	3,263.50	6,776.70
3	Total profit before exceptional items and tax	1,875.20	3,583.00
4	Exceptional items	0.00	0.00
5	Total profit before tax	1,875.20	3,583.00
6	Tax expense
7	Current tax	341.80	897.90
8	Deferred tax	77.50	(116.10)
9	Total tax expenses	419.30	781.80
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0.00	0.00
11	Net Profit Loss for the period from continuing operations	1,455.90	2,801.20
12	Profit (loss) from discontinued operations before tax	0.00	0.00
13	Tax expense of discontinued operations	0.00	0.00
14	Net profit (loss) from discontinued operation after tax	0.00	0.00
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0.00	0.00
16	Total profit (loss) for period	1,455.90	2,801.20
17	Other comprehensive income net of taxes	6.30	4.90
18	Total Comprehensive Income for the period	1,462.20	2,806.10
19	Total profit or loss, attributable to
	Profit or loss, attributable to owners of parent
	Total profit or loss, attributable to non-controlling interests
20	Total Comprehensive income for the period attributable to
	Comprehensive income for the period attributable to owners of parent
	Total comprehensive income for the period attributable to owners of parent non-controlling interests
21	Details of equity share capital
	Paid-up equity share capital	8,638.60	8,638.60
	Face value of equity share capital	2	2
27	Details of debt securities
22	Reserves excluding revaluation reserve
23	Earnings per share
i	Earnings per equity share for continuing operations
	Basic earnings (loss) per share from continuing operations	0.37	0.72
	Diluted earnings (loss) per share from continuing operations	0.37	0.72
ii	Earnings per equity share for discontinued operations
	Basic earnings (loss) per share from discontinued operations	0	0
	Diluted earnings (loss) per share from discontinued operations	0	0
ii	Earnings per equity share
	Basic earnings (loss) per share from continuing and discontinued operations	0.37	0.72
	Diluted earnings (loss) per share from continuing and discontinued operations	0.37	0.72
24	Debt equity ratio
25	Debt service coverage ratio
26	Interest service coverage ratio
27	Disclosure of notes on financial results		Textual Information(1)

Disclosure of notes on financial results

Textual Information(1)	1. The unaudited standalone financial results have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards (Ind AS) - 34 “Interim Financial Reporting” notified under Section 133 of the Companies Act, 2013 (“the Act”) read with the Companies (Indian Accounting Standard Rules), 2015 (as amended from time to time) and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended (Listing Regulations). 2. The unaudited standalone financial results (‘the Statement) of Park Medi World Limited (‘the company’) for the quarter and nine month ended December 2025 were reviewed by the Audit committee on January 28, 2026 and approved by the Board of Directors at its meeting held on January 28, 2026 in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, and have been subjected to limited review by the statutory auditors of the company and have issued an unmodified opinion on the same. 3. The figures for the corresponding quarter and nine months ended December 31, 2024, as reported in these standalone financial results, have been approved by the Company's Board of Directors but have not been reviewed by the statutory auditors. This is pursuant to the requirement of submitting quarterly standalone financial results becoming applicable to the Company with effect from the quarter ended December 31, 2025 pursuant to the listing of its equity shares on BSE Limited ('BSE') and National Stock Exchange of India Limited ('NSE'). The Company's equity shares were listed on the BSE and NSE on December 17, 2025. Hence, this statement of standalone financial results being prepared and submitted in compliance with Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended. 4. The Group's business activity primarily falls within a single reportable business segment namely Healthcare Service and operates primarily in India and accrodingly does not have any additional disclosure to be made under Ind AS 108- Segment Reporting. 5. During the quarter ended December 31, 2025, the Company has completed an initial public offering (IPO) of 56,790,123 equity shares with a face value of INR 2 each at an issue price of INR 162/- per share, comprising fresh issue of 47,530,864 shares and an offer for sale of 9,259,259 shares. The Company’s equity shares were listed on the National Stock exchange of India Limited (NSE) and BSE Limited (BSE) on December 17, 2025. 6. On November 21, 2025, the Government of India notified the four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 - consolidating 29 existing labour laws. The Ministry of Labour & Employment published draft Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations. Based on management’s assessment, there is no adjustments required on gratuity liability arising from the implementation of the codes. The Company continues to monitor the finalisation of Central / State Rules and clarifications from the Government on other aspects of the Labour Code and would provide appropriate accounting effect on the basis of such developments as needed. 7. The company’s Board of Directors has approved on December 19, 2025, to acquire 100% shareholding in K P S Wellness Private Limited and SVPD Healthcare Private Limited on a going concern basis, along with transfer of all rights and interests from existing shareholders for INR 2,450 millions and the transfer is expected to be completed by February 28, 2026. 8. On January 05, 2026, Park Medi World Limited (the Company) considered and approved the acquisition of whole of existing shareholders of Krishna Super-Speciality Hospital for INR 400 million which owns and operates Mahip Hospital Private Limited, a 250 bedded facility, including 70 ICU beds with modular operation theatres and automated laboratories. 9. The utilisation of the IPO proceeds is summarised below: Object of the issue as per prospectus: Utilisation planned as per prospectus Utilised upto December 31, 2025 Amount pending for utilisation as on December 31, 2025 Repayment/ prepayment, in full or in part, of outstanding borrowings availed by our Company and our Subsidiaries 3,800.00 1,430.90 2,369.10 Funding capital expenditure for development of new hospital by our Subsidiary Park Medicity (NCR) 605.00 - 605.00 Funding capital expenditure for purchase of medical equipment by our Company and our Subsidiaries, Blue Heavens and Ratangiri 274.59 - 274.59 Unidentified inorganic acquisitions and general corporate 2,453.18 795.00 1,658.18 Total 7,132.77 2,225.90 4,906.87 10. The unaudited standalone financial results for the quarter and nine months ended 31 December 2025 are available on the Company's website at www.parkhospital.in and also on the website of BSE Limited at www.bseindia.com and National Stock Exchange of India Limited at www.nseindia.com, where the shares of the Company are listed.

Textual Information(1)

1. The unaudited standalone financial results have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards (Ind AS) - 34 “Interim Financial Reporting” notified under Section 133 of the Companies Act, 2013 (“the Act”) read with the Companies (Indian Accounting Standard Rules), 2015 (as amended from time to time) and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended (Listing Regulations). 2. The unaudited standalone financial results (‘the Statement) of Park Medi World Limited (‘the company’) for the quarter and nine month ended December 2025 were reviewed by the Audit committee on January 28, 2026 and approved by the Board of Directors at its meeting held on January 28, 2026 in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, and have been subjected to limited review by the statutory auditors of the company and have issued an unmodified opinion on the same. 3. The figures for the corresponding quarter and nine months ended December 31, 2024, as reported in these standalone financial results, have been approved by the Company's Board of Directors but have not been reviewed by the statutory auditors. This is pursuant to the requirement of submitting quarterly standalone financial results becoming applicable to the Company with effect from the quarter ended December 31, 2025 pursuant to the listing of its equity shares on BSE Limited ('BSE') and National Stock Exchange of India Limited ('NSE'). The Company's equity shares were listed on the BSE and NSE on December 17, 2025. Hence, this statement of standalone financial results being prepared and submitted in compliance with Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended. 4. The Group's business activity primarily falls within a single reportable business segment namely Healthcare Service and operates primarily in India and accrodingly does not have any additional disclosure to be made under Ind AS 108- Segment Reporting. 5. During the quarter ended December 31, 2025, the Company has completed an initial public offering (IPO) of 56,790,123 equity shares with a face value of INR 2 each at an issue price of INR 162/- per share, comprising fresh issue of 47,530,864 shares and an offer for sale of 9,259,259 shares. The Company’s equity shares were listed on the National Stock exchange of India Limited (NSE) and BSE Limited (BSE) on December 17, 2025. 6. On November 21, 2025, the Government of India notified the four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 - consolidating 29 existing labour laws. The Ministry of Labour & Employment published draft Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations. Based on management’s assessment, there is no adjustments required on gratuity liability arising from the implementation of the codes. The Company continues to monitor the finalisation of Central / State Rules and clarifications from the Government on other aspects of the Labour Code and would provide appropriate accounting effect on the basis of such developments as needed. 7. The company’s Board of Directors has approved on December 19, 2025, to acquire 100% shareholding in K P S Wellness Private Limited and SVPD Healthcare Private Limited on a going concern basis, along with transfer of all rights and interests from existing shareholders for INR 2,450 millions and the transfer is expected to be completed by February 28, 2026. 8. On January 05, 2026, Park Medi World Limited (the Company) considered and approved the acquisition of whole of existing shareholders of Krishna Super-Speciality Hospital for INR 400 million which owns and operates Mahip Hospital Private Limited, a 250 bedded facility, including 70 ICU beds with modular operation theatres and automated laboratories. 9. The utilisation of the IPO proceeds is summarised below: Object of the issue as per prospectus: Utilisation planned as per prospectus Utilised upto December 31, 2025 Amount pending for utilisation as on December 31, 2025 Repayment/ prepayment, in full or in part, of outstanding borrowings availed by our Company and our Subsidiaries 3,800.00 1,430.90 2,369.10 Funding capital expenditure for development of new hospital by our Subsidiary Park Medicity (NCR) 605.00 - 605.00 Funding capital expenditure for purchase of medical equipment by our Company and our Subsidiaries, Blue Heavens and Ratangiri 274.59 - 274.59 Unidentified inorganic acquisitions and general corporate 2,453.18 795.00 1,658.18 Total 7,132.77 2,225.90 4,906.87 10. The unaudited standalone financial results for the quarter and nine months ended 31 December 2025 are available on the Company's website at www.parkhospital.in and also on the website of BSE Limited at www.bseindia.com and National Stock Exchange of India Limited at www.nseindia.com, where the shares of the Company are listed.

Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio

Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars		3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-10-2025	01-04-2025
Date of end of reporting period		31-12-2025	31-12-2025
Whether results are audited or unaudited		Unaudited	Unaudited
Nature of report standalone or consolidated		Standalone	Standalone
1	Segment Revenue (Income)
	(net sale/income from each segment should be disclosed)
	Total Segment Revenue
	Less: Inter segment revenue
	Revenue from operations
2	Segment Result
	Profit (+) / Loss (-) before tax and interest from each segment
	Total Profit before tax
	i. Finance cost
	ii. Other Unallocable Expenditure net off Unallocable income
	Profit before tax
3	(Segment Asset - Segment Liabilities)
	Segment Asset
	Total Segment Asset
	Un-allocable Assets	null	null
	Net Segment Asset	null	null
4	Segment Liabilities
	Segment Liabilities
	Total Segment Liabilities
	Un-allocable Liabilities	null	null
	Net Segment Liabilities	null	null
	Disclosure of notes on segments

Other Comprehensive Income

Amount in (Lakhs)

Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-10-2025	01-04-2025
B	Date of end of reporting period	31-12-2025	31-12-2025
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone	Standalone
	Other comprehensive income [Abstract]
1	Amount of items that will not be reclassified to profit and loss
1	Remeasurement of defined benefits plan	8.40	6.60
	Total Amount of items that will not be reclassified to profit and loss	8.40	6.60
2	Income tax relating to items that will not be reclassified to profit or loss	2.10	1.70
3	Amount of items that will be reclassified to profit and loss
	Total Amount of items that will be reclassified to profit and loss
4	Income tax relating to items that will be reclassified to profit or loss
5	Total Other comprehensive income	6.30	4.90

Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (1)

Amount in (Lakhs)

Mode of Fund Raising	Public Issues
Description of mode of fund raising (Applicable in case of others is selected)
Date of Raising Funds	17-12-2025
Amount Raised	77,000.00
Report filed for Quarter ended	31-12-2025
Monitoring Agency	Applicable
Monitoring Agency Name, if applicable	CRISIL Ratings Limited
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders
If Yes, Date of shareholder Approval
Explanation for the Deviation / Variation
Comments of the Audit Committee after review
Comments of the auditors, if any

        Sr.
        Original Object
        Modified Object, if any
        Original Allocation
        Modified allocation, if any
        Funds Utilised
        Amount of Deviation/Variation for the quarter according to applicable
            object
        Remarks if any
    

Signatory Details

Name of signatory	Ajit Gupta
Designation of person	Director
Place	Gurugram
Date	28-01-2026